Related Experiment Video
Updated: Jan 28, 2026
11:45
Quantifying Agonist Activity at G Protein-coupled Receptors
Published on: December 26, 2011
19.8K
GLP-1 receptor agonists and conscious sedation
Eric K Holder1, Amelia Ni2, David Levi3
1Yale University, Department of Orthopaedics and Rehabilitation, New Haven, CT, USA.
Interventional Pain Medicine
|January 26, 2026
Summary
Patients on glucagon-like peptide-1 receptor agonists (GLP-1RA) may continue therapy during elective pain procedures. A thorough risk assessment and shared decision-making are crucial for periprocedural GLP-1RA management.
Area of Science:
- Pain Management
- Endocrinology
- Pharmacology
Background:
- Glucagon-like peptide-1 receptor agonists (GLP-1RA) are increasingly used for type 2 diabetes and obesity.
- Elective pain procedures require careful consideration of medication management.
- Periprocedural management of GLP-1RA therapy is not universally standardized.
Purpose of the Study:
- To summarize evidence and provide recommendations for managing patients on GLP-1RA therapy undergoing elective pain procedures.
- To guide clinicians in periprocedural decision-making for GLP-1RA users.
Main Methods:
- Review of current multi-society guidance statements.
- Evidence summary and synthesis.
- Development of clinical recommendations.
Main Results:
- Patients without specific risk factors can generally continue GLP-1RA therapy during the periprocedural period.
- Comprehensive risk assessment and shared decision-making are essential.
- Conscious sedation should be evaluated case-by-case and is often unnecessary.
Conclusions:
- Periprocedural GLP-1RA management should be individualized.
- Collaboration between patient, prescribing team, performing physician, and anesthesia is vital.
- Minimizing unnecessary interventions like conscious sedation is recommended.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
898
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
898
01:25Drug-Receptor Interaction: Agonist
4.0K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.0K
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
949
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
949
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
493
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
493
01:23Sedatives and Hypnotics: Overview
1.5K
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
1.5K
01:20Sedatives and Hypnotics Drugs: Barbiturates
1.0K
Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A...
1.0K